Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tivozanib - AVEO Oncology/Kyowa Kirin

X
Drug Profile

Tivozanib - AVEO Oncology/Kyowa Kirin

Alternative Names: ASP-4130; AV-951; AV951 cpd; AVE-951; FOTIVDA; Fotivda; KHK-4951; Kil 8951; KRN-951; Tivopath; Tivozanib hydrochloride monohydrate; UNII-172030934T

Latest Information Update: 15 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kirin Brewery
  • Developer Astellas Pharma; AstraZeneca; AVEO Oncology; Bristol-Myers Squibb; EUSA Pharma; Institute Gustave-Roussy; Kyowa Kirin; Northwestern University; Pharmstandard
  • Class Antineoplastics; Eye disorder therapies; Isoxazoles; Quinolines; Small molecules; Urea compounds
  • Mechanism of Action Protein tyrosine kinase inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Renal cell carcinoma
  • Phase II Diabetic macular oedema; Liver cancer; Soft tissue sarcoma; Wet age-related macular degeneration
  • Suspended Colorectal cancer; Fallopian tube cancer; Gastrointestinal cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Triple negative breast cancer
  • No development reported Solid tumours

Most Recent Events

  • 08 May 2024 Pharmacokinetic and Pharmacodyanamic data from a preclinical trial in neovascular age-related macular degeneration released by Kyowa Kirin
  • 31 Jan 2024 Phase-II clinical trials in Wet age-related macular degeneration in Australia, South Korea (Ophthalmic) (NCT06116890)
  • 31 Jan 2024 Phase-II clinical trials in Wet age-related macular degeneration in Japan, USA (Ophthalmic) (NCT06116890)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top